Among the different HDAC isoforms, HDAC6 has become an excellent target for anti-cancer therapeutics11,12, due to its unique structure and ability to deacetylate numerous non-histone proteins, such as α-tubulin and HSP90, as well as a low likelihood to cause toxicity when inhibited.13 The gene discussed is HDAC6; the disease is cancer.